Aldosterone Signaling in Atrial Fibrillation. Another Piece in the Puzzle of Atrial Remodeling

Journal of the American College of Cardiology

Volumn 55, Issue 8, 2010, Pages 771-773

  Korantzopoulos, Panagiotis ^a   Goudevenos, John A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

aldosterone; atrial fibrillation; atrial remodeling; calcium; fibrosis; ionic remodeling; mineralocorticoid receptor; oxidative stress; spironolactone

Indexed keywords

ALDOSTERONE; SPIRONOLACTONE;

AORTA VALVE REGURGITATION; EDITORIAL; EPIDEMIC; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION;

ALDOSTERONE; ANIMALS; ATRIAL FIBRILLATION; HUMANS; SIGNAL TRANSDUCTION;

EID: 76449088802     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.10.032     Document Type: Editorial

References (25)

1. Kannel W.B., and Benjamin E.J. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 27 (2009) 13-24
2. Nattel S., Burstein B., and Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol 1 (2008) 62-73
3. Kourliouros A., Savelieva I., Kiotsekoglou A., Jahangiri M., and Camm J. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 157 (2009) 243-252
4. Iravanian S., and Dudley Jr. S.C. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 5 Suppl 6 (2008) S12-S17
5. Smit M.D., and Van Gelder I.C. Upstream therapy of atrial fibrillation. Expert Rev Cardiovasc Ther 7 (2009) 763-778
6. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., and Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45 (2005) 1243-1248
7. Milliez P., Deangelis N., Rucker-Martin C., et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 26 (2005) 2193-2199
8. Shroff S.C., Ryu K., Martovitz N.L., Hoit B.D., and Stambler B.S. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 17 (2006) 534-541
9. Yang S.S., Han W., Zhou H.Y., et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J (Engl) 121 (2008) 38-42
10. Goette A., Hoffmanns P., Enayati W., Meltendorf U., Geller J.C., and Klein H.U. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 88 (2001) 906-909
11. Dixen U., Ravn L., Soeby-Rasmussen C., et al. Raised plasma aldosterone and natriuretic peptides in atrial fibrillation. Cardiology 108 (2007) 35-39
12. Amir O., Amir R.E., Paz H., Mor R., Sagiv M., and Lewis B.S. Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol 102 (2008) 326-329
13. Gao X., Peng L., Adhikari C.M., Lin J., and Zuo Z. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 13 (2007) 170-177
14. Tsai C.-T., Chiang F.-T., Tseng C.-D., et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 55 (2010) 758-770
15. Pellman J., Lyon R.C., and Sheikh F. Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation. J Mol Cell Cardiol (2009 Sep 12) E-pub ahead of print
16. Korantzopoulos P., Kolettis T.M., Galaris D., and Goudevenos J.A. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 115 (2007) 135-143
17. Ferguson J.D. Stress that causes palpitations: oxidative stress and atrial fibrillation. Heart Rhythm 6 (2009) 941-942
18. Gao G., and Dudley Jr. S.C. Redox regulation, NF-κB, and atrial fibrillation. Antioxid Redox Signal 11 (2009) 2265-2277
19. Johar S., Cave A.C., Narayanapanicker A., Grieve D.J., and Shah A.M. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20 (2006) E846-E854
20. Carnes C.A., Janssen P.M., Ruehr M.L., et al. Atrial glutathione content, calcium current, and contractility. J Biol Chem 282 (2007) 28063-28073
21. Skott O., Uhrenholt T.R., Schjerning J., Hansen P.B., Rasmussen L.E., and Jensen B.L. Rapid actions of aldosterone in vascular health and disease-friend or foe?. Pharmacol Ther 111 (2006) 495-507
22. Funder J.W. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53 (2009) 286-290
23. Dobrev D., and Nattel S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol 52 (2008) 293-297
24. Bukowska A., Schild L., Keilhoff G., et al. Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia. Exp Biol Med (Maywood) 233 (2008) 558-574
25. Benjamin E.J., Chen P.S., Bild D.E., et al. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation 119 (2009) 606-618